Thermo Fisher Scientific Inc. $TMO Shares Purchased by Matrix Asset Advisors Inc. NY

Matrix Asset Advisors Inc. NY grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 22.7% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 27,668 shares of the medical research company’s stock after buying an additional 5,121 shares during the period. Matrix Asset Advisors Inc. NY’s holdings in Thermo Fisher Scientific were worth $13,872,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. WealthBridge Investment Counsel Inc. increased its position in Thermo Fisher Scientific by 2.2% in the 2nd quarter. WealthBridge Investment Counsel Inc. now owns 12,852 shares of the medical research company’s stock valued at $6,443,000 after acquiring an additional 275 shares during the period. Tompkins Financial Corp lifted its position in Thermo Fisher Scientific by 2.4% during the 2nd quarter. Tompkins Financial Corp now owns 1,742 shares of the medical research company’s stock worth $873,000 after acquiring an additional 40 shares during the period. Keudell Morrison Wealth Management grew its stake in shares of Thermo Fisher Scientific by 5.1% in the 2nd quarter. Keudell Morrison Wealth Management now owns 498 shares of the medical research company’s stock valued at $250,000 after purchasing an additional 24 shares during the last quarter. Firethorn Wealth Partners LLC increased its holdings in shares of Thermo Fisher Scientific by 6.3% in the second quarter. Firethorn Wealth Partners LLC now owns 526 shares of the medical research company’s stock valued at $264,000 after purchasing an additional 31 shares during the period. Finally, Tectonic Advisors LLC raised its stake in shares of Thermo Fisher Scientific by 5.5% during the second quarter. Tectonic Advisors LLC now owns 1,869 shares of the medical research company’s stock worth $937,000 after purchasing an additional 97 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Michael D. Shafer sold 25,500 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the sale, the executive vice president owned 20,994 shares in the company, valued at approximately $12,596,400. This represents a 54.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 4,608 shares of the firm’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $586.12, for a total value of $2,700,840.96. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 52,053 shares of company stock worth $30,643,589 in the last quarter. Insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Stifel Nicolaus set a $650.00 price objective on shares of Thermo Fisher Scientific in a research note on Wednesday, August 5th. Morgan Stanley lifted their target price on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an “overweight” rating in a report on Friday, July 24th. Robert W. Baird dropped their price target on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. Barclays raised their price objective on shares of Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an “overweight” rating in a research report on Friday, July 24th. Finally, Wells Fargo & Company lowered their price objective on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and an average target price of $619.41.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $588.17 on Friday. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The firm’s 50-day simple moving average is $529.37 and its 200 day simple moving average is $509.58. Thermo Fisher Scientific Inc. has a 52 week low of $435.27 and a 52 week high of $643.99. The firm has a market capitalization of $217.48 billion, a PE ratio of 31.64, a P/E/G ratio of 2.42 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company had revenue of $11.99 billion during the quarter, compared to analysts’ expectations of $11.71 billion. During the same quarter in the previous year, the business posted $4.28 earnings per share. The firm’s quarterly revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, equities research analysts predict that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s payout ratio is currently 10.11%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.